Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (57)	1/10/2007 6:08:02 PM
From: tuck	Respond to of 269

Endpoints haven't been disclosed at this point; probably will be at initiation. All I know about the IV trial is that all patients will be "Tamiflu naive." HHS has them muzzled at this point. I know they have animal data for IM versus placebo, maybe they don't have it for IM versus Tamiflu to support a head to head trial? That seems unlikely, but to my knowledge, the only PUBLISHED animal data for IM is against placebo. My guess is that they would go head to head with IM in a future study when they get the supporting animal data in front of the regulators. Cheers, Tuck